Scarica l'app Stockscreener
0.512
2.03%
-0.0106
Precedente Chiudi:
$0.5226
Aprire:
$0.51
Volume 24 ore:
294.41K
Relative Volume:
0.29
Capitalizzazione di mercato:
$44.25M
Reddito:
-
Utile/perdita netta:
$-20.31M
Rapporto P/E:
-1.9357
EPS:
-0.2645
Flusso di cassa netto:
$-21.07M
1 W Prestazione:
-16.64%
1M Prestazione:
-22.78%
6M Prestazione:
-44.98%
1 anno Prestazione:
-53.45%
Intervallo 1D:
$0.50
$0.5329
Intervallo di 1 settimana:
$0.50
$0.625
Portata 52W:
$0.50
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Nome
Oncolytics Biotech Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ONCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.512 | 44.25M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-10-06 | Iniziato | Maxim Group | Buy |
| 2021-02-17 | Iniziato | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Borsa (ONCY) Ultime notizie
Oncolytics Biotech(R) Announces First Patient Treated in Company's AWARE-1 Window of Opportunity Study of Pelareorep in Breast Cancer - ACCESS Newswire
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies - Quantisnow
Oncolytics Biotech’s Financial Stability at Risk: Urgent Need for New Financing - MSN
FY2027 EPS Estimate for Oncolytics Biotech Lifted by Analyst - Defense World
What is Leede Financial’s Estimate for ONCY FY2025 Earnings? - Defense World
TSE:ONC FY2025 EPS Estimate Lifted by Leede Financial - Defense World
HC Wainwright Has Bearish Forecast for ONCY FY2029 Earnings - Defense World
HC Wainwright Cuts Earnings Estimates for Oncolytics Biotech - Defense World
Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference - GuruFocus.com
Biotech Advancing Pivotal Phase III Breast Cancer Trial - Streetwise Reports
Bridgewater Systems and Oncolytics Biotech Inc. Under Current Evaluation - ACCESS Newswire
Oncolytics Biotech (NASDAQ:ONCY) Given Buy Rating at HC Wainwright - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Price Target Cut to $3.00 by Analysts at Maxim Group - Defense World
Oncolytics Biotech: Continuing To Justify The Negativity - Seeking Alpha
Oncolytics Biotech’s Promising Advancements and Strategic Developments Drive Buy Rating - TipRanks
Oncolytics price target lowered to $3 from $5 at Maxim - TipRanks
Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - PR Newswire
Sun Valley buying at Canagold Resources (CCM) - The Globe and Mail
Earnings call transcript: Oncolytics Biotech Q4 2024 shows strategic focus By Investing.com - Investing.com Canada
Oncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: - GuruFocus.com
Oncolytics Biotech Inc - MENAFN.COM
Oncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: Promising Cancer Study Results ... - Yahoo Finance
Oncolytics Biotech Advances Cancer Trials with Promising Results - TipRanks
Oncolytics Biotech’s Earnings Call: Clinical Progress Amid Challenges - TipRanks
Stocks In Play: Oncolytics Biotech Inc - Barchart
Stocks In Play: Oncolytics Biotech Inc. - Barchart
Oncolytics Biotech Inc. - Baystreet.ca
Earnings call transcript: Oncolytics Biotech Q4 2024 shows strategic focus - Investing.com
Oncolytics Biotech® Reports Highlights And Financial Results For Q4 And Year-End 2024 - Barchart
Oncolytics Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView
From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025 - Baystreet.ca
Oncolytics reports Q4 EPS (10c) vs. (5c) last year - TipRanks
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024 - Yahoo Finance
Earnings Scheduled For March 7, 2025 - Benzinga
Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Oncolytics Biotech Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Oncolytics Biotech(R) Announces Abstract Published for the 61st Annual Meeting & Exposition of the American Society of Hematology - ACCESS Newswire
Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors - ACCESS Newswire
Oncolytics Biotech(R) Announces Abstract Outlining Potential New Biomarker to be Presented at the 2020 Gastrointestinal Cancers Symposium - ACCESS Newswire
Oncolytics Biotech(R) Announces Spanish Regulatory Approval of AWARE-1 Window of Opportunity Study in Breast Cancer - ACCESS Newswire
Oncolytics Biotech (ONCY) to Release Quarterly Earnings on Friday - Defense World
Oncolytics Biotech(R) Announces Voting Results from the Annual General Meeting of Shareholders - ACCESS Newswire
Oncolytics Biotech (ONCY) Projected to Post Earnings on Friday - MarketBeat
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 - The Malaysian Reserve
Oncolytics Biotech CEO, Matt Coffey, Honored with Scientific Achievement and Innovation Award by BioAlberta - ACCESS Newswire
Oncolytics Biotech(R) Announces Pricing of Its Public Offering of Common Share and Warrants - ACCESS Newswire
Oncolytics Biotech(R) Announces Upcoming Conference Participation - ACCESS Newswire
Oncolytics Biotech(R) to Host Key Opinion Leader Meeting on the Emerging Role of Biomarkers and Oncolytic Viruses in the Treatment of Cancer - ACCESS Newswire
World Cancer Day Sparks Big Questions About Pollution, Genetics, and Innovation - Baystreet.ca
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights - The Globe and Mail
Oncolytics Biotech Inc Azioni (ONCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):